Algorithmic transparency is becoming crucial for FDA evaluations of AI/ML medical devices, as manufacturers face challenges in explaining their models despite high performance metrics.
As AI-powered diagnostic tools gain traction, the FDA is emphasizing the importance of understanding how these algorithms function rather than solely focusing on performance metrics like sensitivity. Manufacturers are increasingly receiving deficiency letters not for underperformance, but for failing to elucidate the workings of their AI systems. The FDA is now prioritizing questions regarding the transparency of the algorithm's logic and the clinician's ability to trust and act on its results.
Historically, manufacturers concentrated on optimizing machine learning models with robust datasets, but this approach falls short when regulatory bodies require clarity on algorithmic processes. The FDA's role extends beyond validating accuracy; it also includes ensuring that clinicians can interpret AI outputs and intervene when necessary. A lack of transparency can hinder clinical decision-making, as illustrated by the growing number of deficiency letters citing insufficient explanations of model outputs and subgroup performance analyses.
The FDA's existing guidelines, while not explicitly labeled as "Explainability Guidance," collectively establish a framework for transparency. Key documents, such as the Good Machine Learning Practice (GMLP) Principles and the 2025 Marketing Submission Recommendations, mandate that manufacturers provide comprehensive documentation to facilitate future model modifications and demonstrate clinical relevance. Manufacturers that overlook these transparency requirements may face compliance gaps that could delay approval.
For successful submissions, the FDA requires traceability of model outputs, clear accountability for AI decisions, and comprehensible information for end-users. By integrating transparency from the outset, manufacturers can streamline the submission process and reduce the risk of lengthy remediation periods. Ultimately, a transparent approach not only meets regulatory expectations but also fosters clinician trust in AI-driven medical devices, paving the way for safer and more effective patient care.